Accelerated total dose infusion of low molecular weight iron dextran is safe and efficacious in chronic kidney disease patients

摘要

Background: Low molecular weight iron dextran (LMWID) is licensed for use as a total dose infusion (TDI) over 4–6 h. In order to improve patient convenience and cost-effectiveness of therapy, we investigated the safety and efficacy of adopting accelerated dosing regimens and compared this with a standard rate LMWID infusion.